

## **TILT Biotherapeutics Regains Rights to TILT-123 in the Greater China Area Upon Termination of License Agreement with Biotheus**

**Helsinki, Finland – 29 Dec 2023:** TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that its out-license to Biotheus Inc. ('Biotheus), a privately held biotech company, has been terminated by mutual agreement, due to a change in the strategic business plan at Biotheus. TILT regains all rights to the commercialization and clinical development of TILT-123 in the Greater China area.

TILT Biotherapeutics' founder and CEO, Akseli Hemminki, said, "Despite good progress in our Phase 1 studies in Europe, U.S. and China, we will now reconcentrate the development efforts for Europe and the US. We regain world-wide licensing rights, which will help us rapidly develop TILT-123 for multiple cancer indications. We continue to explore strategic options for partnering of our powerful oncolytic virus asset, TILT-123, designed to activate T-cells."

TILT and Biotheus had announced (1) in January 2020 a licensing agreement where Biotheus had the right to develop and commercialize TILT-123 in the Greater China Area (including Mainland China, Hong Kong, Taiwan, and Macao).

(1) <https://www.businesswire.com/news/home/20200127005036/en/TILT-Biotherapeutics-Signs-Licensing-Deal-Biotheus-Cancer>

-Ends-